Immune thrombocytopenia: no longer 'idiopathic'.
Immune thrombocytopenia: no longer 'idiopathic'.
复制标题
DOI：
10.3949/ccjm.78gr.10005
复制
发表时间：
2011-06
影响因子：
6.1
通讯作者：
McCrae K
中科院分区：
文献类型：
--
作者：
McCrae K
Immune thrombocytopenia (ITP) is a common hematologic disorder. Its pathogenesis involves both accelerated platelet destruction and impaired platelet production. First-line agents are usually effective initially but do not provide long-term responses. Splenectomy remains an effective long-term therapy, as does rituximab (Rituxan) in a subset of patients. Thrombopoietic agents offer a new alternative, although their place in the overall management of ITP remains uncertain.
